<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05797948</url>
  </required_header>
  <id_info>
    <org_study_id>GZL</org_study_id>
    <nct_id>NCT05797948</nct_id>
  </id_info>
  <brief_title>GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma</brief_title>
  <official_title>Prospective, Single-center, Single-arm, Open-label Study of Obinutuzumab, Zanubrutinib and Lenalidomide Sequential CD19/CD22 CAR-T in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intends to use Obinutuzumab, Zanubrutinib, and Lenalidomide sequential CD19/CD22&#xD;
      CAR-T in the treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma patients. The&#xD;
      main purpose of this study is to explore a new treatment mode for R/R B-NHL patients and&#xD;
      observe the efficacy and safety of this treatment regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will start with 2-4 cycles of combination chem-free therapy with obinutuzumab,&#xD;
      zanubrutinib and lenalidomide, followed by sequential CAR-T therapy. CAR-T therapy with AZA +&#xD;
      FC (Azacitidine +Fludarabine +Cyclophosphamide) conditioning regimen. Targets of CAR-T cells&#xD;
      are CD19/CD22. In this clinical trial, ORR, CRR, OS, PFS, AE and other indicators were used&#xD;
      to observe the safety and efficacy of this sequential therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 1, 2022</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR) after GZL therapy</measure>
    <time_frame>At the end of GZL therapy (2-4 cycles, each cycle is 21days)</time_frame>
    <description>the rate of patients who achieved CR or PR after GZL therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete response rate (CRR) after CAR-T</measure>
    <time_frame>Within 3 months after CAR-T therapy</time_frame>
    <description>the best rate of patients who achieved CR after CAR-T therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS) after CAR-T</measure>
    <time_frame>up to 24 months after the end of last patient's treatment</time_frame>
    <description>PFS will be assessed from the GZL combination therapy given to date of progression, relapse, death or end of follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events, treatment-related adverse events and serious adverse events</measure>
    <time_frame>Initiation of GZL therapy until 30 days after CAR-T therapy</time_frame>
    <description>The safety and tolerability of the therapeutic regimen measured by the incidence of Treatment-Emergent Adverse Event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) after CAR-T</measure>
    <time_frame>Within 3 months after CAR-T therapy</time_frame>
    <description>The best rate of patients who achieved CR or PR after CAR-T therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) after CAR-T</measure>
    <time_frame>up to 24 months after the end of last patient's treatment</time_frame>
    <description>OS will be assessed from the GZL combination therapy given to date of death or end of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response(DOR) after CAR-T</measure>
    <time_frame>up to 24 months after the end of last patient's treatment</time_frame>
    <description>DOR will be assessed from the date of CAR-T infusion to the date of progression, relapse, death or end of follow-up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Relapsed or Refractory B-cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>GZL sequential CD19/CD22 CAR-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I (combined immunotherapy period):&#xD;
2-4 cycle of combination chem-free therapy with Obinutuzumab, Zanubrutinib and Lenalidomide . Each cycle is 21 days.&#xD;
Phase II (CAR-T therapy):&#xD;
CAR-T therapy with AZA + FC (Azacitidine, Fludarabine and Cyclophosphamide) conditioning regimen. Targets of CAR-T cells are CD19/CD22.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>Obinutuzumab Injection 1000mg ivgtt C1-C4 d1；</description>
    <arm_group_label>GZL sequential CD19/CD22 CAR-T</arm_group_label>
    <other_name>Gazyva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanubrutinib</intervention_name>
    <description>Zanubrutinib 160mg (2 capsules) oral bid；</description>
    <arm_group_label>GZL sequential CD19/CD22 CAR-T</arm_group_label>
    <other_name>Brukinsa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Lenalidomide 25mg (1 capsule) oral C1-C4 d1-d10.</description>
    <arm_group_label>GZL sequential CD19/CD22 CAR-T</arm_group_label>
    <other_name>Anxian</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD19/CD22 CAR-T</intervention_name>
    <description>Targets of CAR-T cells are tandem CD19/CD22. 1 * 10 ^ 7/kg dual-target CAR-T cells were reinfused with 10%, 30% and 60% of the total dose on d1, d2, d3 respectively.</description>
    <arm_group_label>GZL sequential CD19/CD22 CAR-T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine For Injection</intervention_name>
    <description>Azacitidine For Injection 100mg i.h. d1-d5;</description>
    <arm_group_label>GZL sequential CD19/CD22 CAR-T</arm_group_label>
    <other_name>Anyve</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 300mg/m2 ivgtt d3-d5;</description>
    <arm_group_label>GZL sequential CD19/CD22 CAR-T</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 300mg/m2 ivgtt d3-d5.</description>
    <arm_group_label>GZL sequential CD19/CD22 CAR-T</arm_group_label>
    <other_name>Endoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed CD22 + and/or CD19 + aggressive B-cell non-Hodgkin lymphoma&#xD;
             (NHL), including the following types as defined by World Health Organization (WHO)&#xD;
             2016:&#xD;
&#xD;
             Diffuse large B-cell lymphoma (DLBCL); High grade B-cell lymphoma (HGBL); Primary&#xD;
             mediastinal large B-cell lymphoma(PMBCL); T cell/histiocyte-rich large B-cell lymphoma&#xD;
             (THRBCL); High grade follicular cell lymphoma Grade 3b (3bFL); Mantle cell lymphoma&#xD;
             (MCL) except indolent; Other aggressive B-cell lymphomas.&#xD;
&#xD;
          2. Disease refractory to first-line therapy or early relapse within 12 months of last&#xD;
             treatment.&#xD;
&#xD;
          3. Relapse or progressive disease (PD) ≥ 3 months after targeted CD19 therapy including&#xD;
             CD19 CAR T cells or anti-CD19/anti-CD3.&#xD;
&#xD;
          4. Successful leukapheresis assessment and T-cell preculture.&#xD;
&#xD;
          5. Life expectancy &gt; 3 months.&#xD;
&#xD;
          6. Appropriate organ function:&#xD;
&#xD;
             Creatinine &lt; 1.6 mg/dL (140 µmol/L) or creatinine clearance ≥ 60ml/min; Alanine&#xD;
             aminotransferase (ALT)/aspartate aminotransferase (AST) &lt; 3 × upper limit of normal;&#xD;
             Bilirubin &lt; 2.0 mg/dL unless subject has Gilbert 's syndrome (&lt; 3.0 mg/dL); Pulmonary&#xD;
             reserve ≤ Grade 1 dyspnea and SPO2 &gt; 91%; Cardiac ejection fraction ≥ 50% in the&#xD;
             absence of oxygen, no evidence of pericardial effusion as determined by echocardiogram&#xD;
             (ECHO), and no clinically significant electrocardiogram (ECG) findings.&#xD;
&#xD;
          7. Adequate bone marrow reserve was defined as:&#xD;
&#xD;
             Absolute neutrophil count (ANC) &gt; 1000/mm3; Absolute lymphocyte count (ALC) ≥ 300/mm3;&#xD;
             Platelet count ≥ 50,000/mm3. Hemoglobin &gt; 7.0 mg/dL.&#xD;
&#xD;
          8. Measurable or evaluable lesions according to &quot;IWG response criteria for malignant&#xD;
             lymphoma&quot; (Cheson 2014).&#xD;
&#xD;
          9. Patients have the ability to understand and are willing to provide written informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. severe liver and kidney dysfunction (alanine aminotransferase, bilirubin, creatinine &gt;&#xD;
             3 times the upper limit of normal);&#xD;
&#xD;
          2. the presence of structural heart disease, and lead to clinical symptoms or abnormal&#xD;
             heart function (NYHA ≥ 2);&#xD;
&#xD;
          3. uncontrolled active infection;&#xD;
&#xD;
          4. the presence of other tumors requiring treatment or intervention;&#xD;
&#xD;
          5. the current or expected need for systemic corticosteroid therapy;&#xD;
&#xD;
          6. pregnant or lactating women.&#xD;
&#xD;
          7. Other psychological conditions that prevent patients from participating in the study&#xD;
             or signing informed consent;&#xD;
&#xD;
          8. According to the investigator 's judgment, the subject is unlikely to complete all&#xD;
             protocol-required study visits or procedures, including follow-up visits, or fail to&#xD;
             meet the requirements for participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>March 22, 2023</study_first_submitted>
  <study_first_submitted_qc>March 22, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2023</study_first_posted>
  <last_update_submitted>March 22, 2023</last_update_submitted>
  <last_update_submitted_qc>March 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Humanized anti-CD20 monoclonal antibody</keyword>
  <keyword>BTK Inhibitor</keyword>
  <keyword>Immunomodulators</keyword>
  <keyword>CAR-T</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Obinutuzumab</mesh_term>
    <mesh_term>Zanubrutinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All the data would be available at the First Affiliated Hospital and other researchers after the end of the study.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>after the end of the study</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

